SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Pulmonary, Allergy and Critical Care Medicine



[Return To Index page]
photo Sally E. Wenzel, MD

Professor of Medicine

Director, University of Pittsburgh Asthma Institute at UPMC/UPSOM

Subsection Chief of Allergy, Division of Pulmonary, Allergy & Critical Care Medicine

UPMC Chair of Translational Airway Biology

Email: wenzelse@upmc.edu

Phone: 412-864-2615

Contact
Office: UPMC Montefiore Hospital, NW931
3459 Fifth Avenue
Pittsburgh, PA 15213
 
Phone: 412-864-2615
Fax: 412-605-1999
E-mail: wenzelse@upmc.edu
Education and Training
Education
BS, University of Florida, 1978
MD, University of Florida, 1981
Training
Internship in Internal Medicine, Wake Forest Univ Baptist Medical Center, 1982
Residency in Internal Medicine, Wake Forest Univ Baptist Medical Center, 1984
Fellowship In Pulmonary Medicine, Medical College of Virginia, 1986
Research Interest
In relation to her clinical interest in asthma, Dr. Wenzel has developed a strong translational program to study the pathobiology and mechanisms of the human disease. She is one of seven NHLBI funded investigators in the Severe Asthma Research Program (SARP) network and Co-directs a PO1 on severe asthma with her collaborator, Dr. Anuradha Ray. Through SARP and her own efforts, Dr. Wenzel has accumulated a clinical database of over 500 subjects with asthma and healthy controls, most of whom have matching airway tissue, cells and sputum/lavage. Her lab is one of few which is able to match an extensive clinical phenotype of a subject with responses at a cellular/molecular level. She is developing rich databases of gene expression in asthma. Her current bench-lab interests include the role of epithelial cells in controlling airway inflammatory responses, oxidative and nitrative stress, as well as their interactions with mast cells and Th1 immune responses. She currently heads the University of Pittsburgh Asthma Institute@UPMC, and holds the UPMC Chair in Translational Airway Biology.
Clinical Interest
Dr. Wenzel has had a passion for understanding and improving the treatment of asthma, in particular severe asthma. She served as Chair of the original ATS workshop and the following ERS-ATS guidelines on severe asthma which developed the definition and approaches to treatment of severe asthma. Dr. Wenzel has been listed as one of Castle Connelly’s top doctors in America for over 15 years. She has worked to promote severe asthma as a disease whose pathogenesis goes beyond issues of non-compliance/adherence. Her studies of asthma phenotypes have led the field in understanding the complexities of asthma and she is internationally recognized for her efforts in this area. To this end, she and her colleagues recently described a new asthmatic disease, called “Asthmatic Granulomatosis”. This severe asthma-like disease responds to alternative medications, beyond steroids.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Wenzel, S, Castro, M, Corren, J, Maspero, J, Wang, L, Zhang, B, Pirozzi, G, Sutherland, ER, Evans, RR, Joish,VN, Eckert, L, Graham, NM, Stahl, N, Yancopoulos, GD, Louis-Tisserand, M, Teper, A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; Jul2;388(10039): 31-44.
Raundhal, M, Morse, C, Khare, A, Oriss, TB, Milosevic, J, Trudeau, J, Huff, R, Pilewski, J, Holguin, F, Kolls, J, Wenzel, S, Ray, P, Ray, A. High IFN-y and low SLPI mark severe asthma in mice and humans. J Clin Invest. 2015; Aug 3;125(8): 3037-50.
Wenzel, SE, Wang, L, Pirozzi, G. Dupilumab in persistent asthma. N Engl J Med. 2013; Sep 26;369(13): 1276.
Zhao, J, O'Donnell, VB, Balzar, S, St. Croix, CM, Trudeau, JB, Wenzel, SE. 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. Proc Natl Acad Sci USA. 2011; Aug 23;108(34): 14246-51.
Wenzel, SE. Asthma phenotypes: Evolution from clinical to molecular approaches. Nat med. 2012; May 4;18(5): 716-25.
Albano, GD, Zhao, J, Etling, EB, Park, SY, Hu, H, Trudeau, JB, Profita, M, Wenzel, SE. IL-13 desensitizes ß2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism. J Allergy Clin Immunol. 2015; May;135(5): 1144-53.
Modena, BD, Tedrow, JR, Milosevic, J, Bleeker, ER, Meyers, DA, Wu, W, Bar-Joseph, Z, Erzurum, SC, Gason, BM, Busse, WW, Jarjour, NN, Kaminski, N, Wenzel, SE. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med. 2014; Dec 15;190(12): 1363-72.
Wu, W, Bleecker, E, Moore, W, Busse, WW, Castro, M, Chung, KF, Calhoun, WJ, Erzurum, S, Gaston, B, Israel, E, Curran-Everett, D, Wenzel, SE. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014; May;133(5): 1280-8.
Fajt, ML, Gelhaus, SL, Freeman, B, Uvalle, C, Trudeau, JB, Holguin, F, Wenzel, SE. Prostaglandin D2 pathway upregulation: Relation to asthma severity, control and Th2 inflammation. J Allergy Clin Immunol. 2013; Jun;131(6): 1504-1512.
Wenzel, SE, Wilbraham, D, Fuller, R, Getz, EB, Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; Oct 20;370(9596): 1396-8.
Sponsored Research/Activities
Title: Mechanisms of Antigen-Induced Tolerance in the Lung
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI048927
Start Year: 2016
End Year: 2021
Title: SPLUNC1 in Severe Asthma
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL125128
Start Year: 2015
End Year: 2019
Title: Toward PanOmic and Personalized Association Study of Complex Diseases - A New Statistical and Computational Paradigm for Personalized Medicine
Role: Co-Investigator
Funding Agency: Carnegie-Mellon University/National Institute of General Medical Science
Grant Number: R01 GM114311
Start Year: 2015
End Year: 2019
Title: Adiposity and Airway Inflammation in HIV-Associated Airway Disease
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R56 HL128134
Start Year: 2015
End Year: 2016
Title: Asthmanet: Phenotypic Influences on Asthma Treatment (ALFA Protocol)
Role: Co-Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL098115
Start Year: 2014
End Year: 2016
Title: Understanding Severe Asthma Using an Experimental Model
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL113956
Start Year: 2013
End Year: 2017
Title: Asthmanet: Phenotypic Influences on Asthma Treatment - STICS Protocol
Role: Co-Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL098115
Start Year: 2013
End Year: 2016
Title: Asthmanet: Phenotypic Influences on Asthma Treatment (BARD Protocol)
Role: Co-Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL098115
Start Year: 2013
End Year: 2016
Title: AsthmaNet: Phenotypic Influences on Asthma Treatments - SIENA
Role: Co-Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL098115
Start Year: 2013
End Year: 2016
Title: IRC 003 Study Implementation
Role: Co-Investigator
Funding Agency: Social and Scientific Systems, Inc./National Cancer Institute
Start Year: 2013
End Year: 2014
Title: Th2 Inflammation Promotes Airway Surface Liquid Dehydration
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL112863
Start Year: 2012
End Year: 2017
Title: Severe Asthma Research Program
Role: Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL109086
Start Year: 2012
End Year: 2016
Title: Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: U10 HL109152
Start Year: 2011
End Year: 2017
Title: Clinical Coordinating Center for the Severe Asthma Research Program (SARP)
Role: Co-Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL109086
Start Year: 2011
End Year: 2017
Title: Redox-Derived Pulmonary Anti-Inflammatory Mediators
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL064937
Start Year: 2011
End Year: 2016
Title: IRC 003 Study Implementation
Role: Co-Investigator
Funding Agency: Social and Scientific Systems, Inc./National Institute of Allergy & Infectious Diseases
Start Year: 2011
End Year: 2013
Title: Amplification of IL-4Ralpha Signaling Pathways in Human Airways though 15 LO1
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R01 AI040600
Start Year: 2010
End Year: 2016
Title: Data Coordinating Center for the NHLBI Asthma Network (AsthmaNet)
Role: Co-Principal Investigator
Funding Agency: Penn State/National Heart, Lung, & Blood Institute
Grant Number: U10 HL098115
Start Year: 2010
End Year: 2014
Title: Severe Asthma Research Program (SARPII) Imaging Core
Role: Co-Investigator
Funding Agency: Washington University/National Heart, Lung, & Blood Institute
Grant Number: R01 HL091762
Start Year: 2008
End Year: 2013
Notable Achievements
ATS Scientific Achievement Award, 2010
ATS Foundation Breathing for LIfe Award, 2016
Member, American Association of Physicians, 2014
Elizabeth Rich Award (ATS), 2005